{
  "symbol": "ABBV",
  "price": 244.38,
  "beta": 0.525,
  "volAvg": 5237446,
  "mktCap": 431711505868,
  "lastDiv": 6.47,
  "range": "163.81-244.81",
  "changes": 12.84,
  "companyName": "AbbVie Inc.",
  "currency": "USD",
  "cik": "0001551152",
  "isin": "US00287Y1091",
  "cusip": "00287Y109",
  "exchange": "New York Stock Exchange",
  "exchangeShortName": "NYSE",
  "industry": "Drug Manufacturers - General",
  "website": "https://www.abbvie.com",
  "description": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh√ßet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.",
  "ceo": "Robert A. Michael CPA",
  "sector": "Healthcare",
  "country": "US",
  "fullTimeEmployees": "55000",
  "phone": "847 932 7900",
  "address": "1 North Waukegan Road",
  "city": "North Chicago",
  "state": "IL",
  "zip": "60064-6400",
  "dcfDiff": -315.34031,
  "dcf": 559.7203070548286,
  "image": "https://images.financialmodelingprep.com/symbol/ABBV.png",
  "ipoDate": "2013-01-02",
  "defaultImage": false,
  "isEtf": false,
  "isActivelyTrading": true,
  "isAdr": false,
  "isFund": false
}